Get the Stockscreener App
0.60
0.56%
-0.0034
After Hours:
.60
Longeveron Inc stock is traded at $0.60, with a volume of 487.72K.
It is down -0.56% in the last 24 hours and down -28.49% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.6034
Open:
$0.6
24h Volume:
487.72K
Relative Volume:
1.12
Market Cap:
$11.91M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.0897
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
-11.98%
1M Performance:
-28.49%
6M Performance:
-54.89%
1Y Performance:
-67.91%
1-Day Range:
$0.5906
$0.63
1-Week Range:
$0.5906
$0.6855
52-Week Range:
$0.5906
$2.24
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.60 | 12.87M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Take off with Longeveron Inc (LGVN): Get ready for trading - Setenews
What data driven models say about Longeveron Inc.’s futureJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Longeveron to present Alzheimer’s treatment data at CTAD 2025 By Investing.com - Investing.com Nigeria
Will Longeveron Inc. stock remain a Wall Street favorite2025 Dividend Review & Community Shared Stock Ideas - newser.com
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) Presenting Laromestrocel CLEAR MIND Data at CTAD 2025 - Stock Titan
Why analysts upgrade Longeveron Inc. stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Visualizing Longeveron Inc. stock with heatmapsJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
What drives Longeveron Inc stock priceHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
What dividend safety score for Longeveron Inc. stockWeekly Risk Report & Entry Point Confirmation Signals - newser.com
How Longeveron Inc. stock compares to growth peersJuly 2025 Big Picture & Expert Verified Movement Alerts - Fundação Cultural do Pará
Is Longeveron Inc. stock recession proof2025 Volume Leaders & High Accuracy Investment Signals - Fundação Cultural do Pará
Longeveron Faces Nasdaq Delisting Notice for Stock Price - MSN
Will Longeveron Inc. stock continue dividend increasesPortfolio Growth Summary & Weekly High Return Stock Forecasts - newser.com
Longeveron secures patent for stem cell therapy targeting aging frailty By Investing.com - Investing.com Nigeria
Longeveron announces resignations of two board members By Investing.com - Investing.com Australia
Longeveron granted U.S. patent for administration of MSCs - TipRanks
How does Longeveron Inc (LGVN) change from a tortoise to a hare? - Setenews
Longeveron secures patent for stem cell therapy targeting aging frailty - Investing.com
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - The Manila Times
Longeveron Announces Resignation of Board Members - TipRanks
Longeveron announces resignations of two board members - Investing.com
What analysts say about Longeveron Inc stockMarket Volatility Update & Superior Trading Ideas - earlytimes.in
Can you recover from losses in Longeveron Inc.2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Analysts Offer Predictions for Longeveron FY2025 Earnings - Defense World
How to recover losses in Longeveron Inc. stock2025 Bull vs Bear & Safe Capital Growth Tips - newser.com
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):